Lys-γ3-MSH(human)
| Code | Size | Price |
|---|
| TAR-TP2267-1mg | 1mg | £426.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Pro-opiomelanocortin (POMC) derived peptide that stimulates lipolysis
CAS:
156159-18-1
Formula:
C128H193N45O39S
Molecular Weight:
3018.27
Purity:
0.98
SMILES:
CC(C)([H])[C@]([H])(N=C(O)[C@]([H])(C/C1=C/C=C(/O)C=C1)N=C(O)[C@](N)([H])CCCCN)C(O)=N[C@@]([H])(CC[S]C)C(O)=NCC(O)=N[C@@]([H])(C/C2=C/N=CN2)C(O)=N[C@@]([H])(C/C3=C/C=CC=C3)C(O)=N[C@@]([H])(CCCNC(=N)N)C(O)=N[C@@]([H])(C/C4=C/NC5=CC=CC=C45)C(O)=N[C@@]([H])(CC(=O)O)C(O)=N[C@@]([H])(CCCNC(=N)N)C(O)=N[C@@]([H])(C/C6=C/C=CC=C6)C(O)=NCC(O)=N[C@@]([H])(CCCNC(=N)N)C(O)=N[C@@]([H])(CCCNC(=N)N)C(O)=N[C@@]([H])(CC(=N)O)C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CO)C(O)=NCC(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CO)C(O)=NCC(O)=N[C@](C)([H])C(O)=NCC(O)=N[C@@]([H])(CCC(=N)O)C(=O)O
References
Lainchbury M, Matthews T P, McHardy T, et al. Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino) pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. Journal of medicinal chemistry, 2012, 55(22): 10229-10240.
McNeely S C, Burke T F, DurlandBusbice S, et al. Abstract A108: LY2606368, a second generation Chk1 inhibitor, inhibits growth of ovarian carcinoma xenografts either as monotherapy or in combination with standard-of-care agents. Molecular Cancer Therapeutics, 2011, 10(Supplement 1): A108.
Wu W, Bi C, Bence A K, et al. Antitumor activity of Chk1 inhibitor LY2606368 as a single agent in SW1990 human pancreas orthotopic tumor model. Cancer Research, 2012, 72(8 Supplement): 1776.